metaEvidence - overview

button bars forest bayes pooled summary circles


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
laNSCLC - M - all population locally advanced NSCLC - maintenance (M) laNSCLC - M - all population
versus placebo
	durvalumab alone vs. placebo	1	none	inconclusive results for: DOR; DOR (extension); AE (any grade); AE (grade 3-4); AE leading to death (grade 5); AE leading to treatment discontinuation (any grade); SAE (any grade); TRAE (any grade); TRAE (grade 3-4); TRAE leading to death (grade 5); Asthenia TRAE (grade 3-4); Cough TRAE (grade 3-4); Decreased appetite TRAE (grade 3-4); Diarrhoea TRAE (grade 3-4); Dyspnoea TRAE (grade 3-4); Hyperthyroidism TRAE (grade 3-4); Hypothyroidism TRAE (grade 3-4); Nausea TRAE (grade 3-4); Pneumonitis TRAE (grade 3-4); Pruritus TRAE (grade 3-4); Rash TRAE (grade 3-4); Anaemia AE (grade 3-4); Arthralgia AE (grade 3-4); Asthenia AE (grade 3-4); Back pain AE (grade 3-4); Constipation AE (grade 3-4); Cough AE (grade 3-4); Decreased appetite AE (grade 3-4); Diarrhoea AE (grade 3-4); Dyspnoea AE (grade 3-4); Fatigue AE (grade 3-4); Headache AE (grade 3-4); Hypothyroidism AE (grade 3-4); Nausea AE (grade 3-4); Pneumonia AE (grade 3-4); Pneumonitis AE (grade 3-4); Pruritus AE (grade 3-4); Pyrexia AE (grade 3-4); Rash AE (grade 3-4)	statistically conclusive 32 % decrease in deaths (OS) but the degree if certainty is unassessable suggested 28 % decrease in deaths (OS) (extension) but the degree if certainty is unassessable suggested 45 % decrease in PFS (extension) but the degree if certainty is unassessable statistically conclusive 48 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable statistically conclusive 2.0-fold increase in objective responses (ORR) but the degree if certainty is unassessable	-

laNSCLC - M - all population locally advanced NSCLC - maintenance (M) laNSCLC - M - all population

versus placebo